相关实验视频

Updated: Jul 18, 2025

Author Spotlight: A Computational Approach to Decipher Amino Acid Preferences in Multispecific Protein-Protein Interactions

Author Spotlight: A Computational Approach to Decipher Amino Acid Preferences in Multispecific Protein-Protein Interactions

Published on: January 26, 2024

ADP-Fuse:一种新的双层机器学习预测器,用于使用多视图信息识别抗糖尿病和糖尿病类型

Shaherin Basith¹, Nhat Truong Pham², Minkyung Song³

¹Department of Physiology, Ajou University School of Medicine, Suwon, 16499, Republic of Korea.

Computers in biology and medicine

|August 24, 2023

概括

一个新的计算工具,ADP-Fuse,准确地识别和类型抗糖尿病 (ADPs),加速新型糖尿病治疗的发现. 这一框架有助于开发新药来对抗糖尿病及其严重的健康并发症.

科学领域:

生物化学和生物信息学
计算生物学计算生物学
药物发现药物发现药物发现

背景情况:

糖尿病是一种严重并发症的全球重大健康问题,需要新的治疗策略.
抗糖尿病 (ADP) 通过调节胰岛素的产生,显示出糖尿病治疗的前景.
目前的矿工具不足以发现新型ADP,突出显示了对先进计算方法的需求.

研究的目的:

开发和验证ADP-Fuse,这是一种用于准确识别和分类抗糖尿病的新型计算框架.
为了评估各种特征和机器学习算法的有效性,用于ADP预测.
为公共访问提供一个用户友好的Web服务器,以促进ADP发现.

主要方法:

对22个序衍生特征和8个机器学习算法的全面评估.
开发一个双层预测框架 (ADP-Fuse),集成多视图信息.
在特征重要性分析中应用夏普利添加物扩张方法.

主要成果:

与单一特征模型相比,ADP-Fuse在识别ADP并将其分类为1型和2型方面表现出更高的准确性.
该框架有效地整合了多视图信息,以提高预测性能.
功能重要性分析为ADP预测的关键描述符提供了洞察力.

结论:

ADP-Fuse是一个强大而准确的计算工具,用于识别和分类抗糖尿病.
开发的Web服务器大大促进了新型ADP的发现.
这一框架预计将推动抗糖尿病研究和药物开发领域的发展.

关键词:

抗糖尿病是一种抗糖尿病.生物信息学是一种生物信息学.机器学习机器学习多视图信息多视图信息序列分析是指进行序列分析.堆叠集体学习堆叠集体学习

更多相关视频

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Biosensor-based High Throughput Biopanning and Bioinformatics Analysis Strategy for the Global Validation of Drug-protein Interactions

Published on: December 1, 2020

An In Ovo Model for Testing Insulin-mimetic Compounds

An In Ovo Model for Testing Insulin-mimetic Compounds

Published on: April 23, 2018

相关概念视频

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...

Diabetes Mellitus: Overview and Type I Subtype

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...